Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2021 Apr;10(2):85-93. doi: 10.1159/000514312. Epub 2021 Feb 15.
Abstract
摘要
相似文献
1
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.阿替利珠单抗联合贝伐单抗治疗失败后肝细胞癌的序贯治疗
Liver Cancer. 2021 Apr;10(2):85-93. doi: 10.1159/000514312. Epub 2021 Feb 15.
2
Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series.肝癌患者在使用乐伐替尼后接受阿替利珠单抗联合贝伐单抗治疗出现的甲状腺功能障碍：病例系列报道
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231164488. doi: 10.1177/2050313X231164488. eCollection 2023.
3
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.阿替利珠单抗联合贝伐单抗用于晚期肝细胞癌临床实践的初步经验
Cancer Diagn Progn. 2021 May 3;1(2):83-88. doi: 10.21873/cdp.10012. eCollection 2021 May-Jun.
4
Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis.优化晚期肝细胞癌的序贯系统治疗：一项决策分析
Cancers (Basel). 2020 Jul 31;12(8):2132. doi: 10.3390/cancers12082132.
5
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
6
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
7
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
8
Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.序贯系统治疗肝细胞癌：二线竞争者。
World J Gastroenterol. 2020 Apr 28;26(16):1888-1900. doi: 10.3748/wjg.v26.i16.1888.
9
Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence.雷莫西尤单抗：肝细胞癌患者的二线治疗选择——证据综述
Cancer Manag Res. 2020 May 20;12:3721-3729. doi: 10.2147/CMAR.S216220. eCollection 2020.
10
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.索拉非尼序贯瑞戈非尼或乐伐替尼治疗肝细胞癌患者的安全性和疗效
Hepatol Res. 2021 Feb;51(2):190-200. doi: 10.1111/hepr.13588. Epub 2020 Dec 4.
引用本文的文献
1
Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.多学科策略，包括局部治疗，以在肝细胞癌患者接受阿替利珠单抗加贝伐单抗治疗后实现无药状态。
Oncol Lett. 2025 Jul 31;30(4):466. doi: 10.3892/ol.2025.15212. eCollection 2025 Oct.
2
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real-World Analysis of the IMMUreal Cohort.阿替利珠单抗联合贝伐单抗治疗肝细胞癌后全身治疗的治疗顺序：IMMUreal队列的真实世界分析
Aliment Pharmacol Ther. 2025 Jun;61(11):1755-1766. doi: 10.1111/apt.70090. Epub 2025 Apr 4.
3
Metabolites and metabolic pathway reactions links to sensitization of immunotherapy in pan-cancer.代谢物和代谢途径反应与泛癌免疫治疗致敏作用的联系。
Mol Ther Oncol. 2025 Jan 14;33(1):200933. doi: 10.1016/j.omton.2025.200933. eCollection 2025 Mar 20.
4
Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.美国不可切除肝细胞癌中影响一线治疗的医疗状况或合并症的患病率。
Future Oncol. 2025 Feb;21(3):313-319. doi: 10.1080/14796694.2024.2444874. Epub 2025 Jan 15.
5
The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy.晚期肝细胞癌治疗趋势：免疫治疗与靶向治疗联合。
Curr Treat Options Oncol. 2024 Oct;25(10):1239-1256. doi: 10.1007/s11864-024-01246-9. Epub 2024 Sep 11.
6
Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis.一线阿替利珠单抗联合贝伐单抗治疗失败后，索拉非尼或仑伐替尼用于晚期肝细胞癌的疗效和安全性：一项系统评价和荟萃分析
Cancers (Basel). 2024 Aug 10;16(16):2813. doi: 10.3390/cancers16162813.
7
Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?肝细胞癌免疫检查点抑制剂治疗失败后的二线治疗：酪氨酸激酶抑制剂、免疫治疗重试还是局部区域治疗？
Liver Cancer. 2023 Nov 13;13(3):246-255. doi: 10.1159/000534303. eCollection 2024 Jun.
8
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit.对于不可切除的肝细胞癌，在阿替利珠单抗联合贝伐单抗治疗失败后，局部区域治疗与全身治疗相结合可带来生存获益。
Am J Cancer Res. 2023 Nov 15;13(11):5482-5492. eCollection 2023.
9
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.阿替利珠单抗联合贝伐单抗加或不加根治性转化治疗经动脉化疗栓塞不适合的中期肝细胞癌患者实现完全缓解和无药状态：一项多中心概念验证研究
Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep.
10
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.肝细胞癌系统性治疗的新时代：从一线治疗到最佳序贯治疗。
Curr Oncol. 2023 Sep 26;30(10):8774-8792. doi: 10.3390/curroncol30100633.
本文引用的文献
1
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.雷莫西尤单抗对晚期肝细胞癌患者ALBI分级的影响：REACH和REACH-2研究结果
JHEP Rep. 2020 Nov 13;3(2):100215. doi: 10.1016/j.jhepr.2020.100215. eCollection 2021 Apr.
2
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.对于先前接受PD-1/PD-L1检查点阻断治疗失败的不可切除肝细胞癌患者，乐伐替尼治疗的探索性分析
Cancers (Basel). 2020 Oct 20;12(10):3048. doi: 10.3390/cancers12103048.
3
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.钆塞酸二钠增强磁共振成像可预测肝细胞癌中WNT/β-连环蛋白突变及对免疫检查点抑制剂治疗的耐药性。
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
4
Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma.雷莫西尤单抗在日本不可切除肝细胞癌患者中的疗效优于全球总体人群。
Liver Cancer. 2020 Jun;9(3):232-244. doi: 10.1159/000507889. Epub 2020 May 29.
5
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
6
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.肿瘤成纤维细胞生长因子受体4水平可预测晚期肝细胞癌患者使用乐伐替尼的疗效。
Clin Transl Gastroenterol. 2020 May;11(5):e00179. doi: 10.14309/ctg.0000000000000179.
7
Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.双重血管内皮生长因子受体和成纤维细胞生长因子受体抑制引发抗肿瘤免疫并增强肝细胞癌中的程序性细胞死亡蛋白1检查点阻断作用
Liver Cancer. 2020 Jun;9(3):338-357. doi: 10.1159/000505695. Epub 2020 Feb 25.
8
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
9
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
10
A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.肝细胞癌全身治疗的新时代：阿替利珠单抗联合贝伐珠单抗联合疗法。
Liver Cancer. 2020 Apr;9(2):119-137. doi: 10.1159/000505189. Epub 2020 Mar 5.
Zotero 插件